Ann Arbor, Michigan — August 7, 2025 — Leads & Copy — Esperion (NASDAQ: ESPR) announced on August 5, 2025, the grant of 73,500 restricted stock units (RSUs) to 12 new employees under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is exclusively for granting equity awards to new employees or those returning after a break in employment, as an incentive for joining Esperion, in accordance with NASDAQ Listing Rule 5635(c)(4). Each RSU will vest as to 25% of the shares on the first anniversary of the vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter, contingent upon continued employment with Esperion. The RSUs are subject to the terms of Esperion’s 2017 Inducement Equity Incentive Plan and the RSU agreement.
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline.
Contact:
Alina Venezia, investorrelations@esperion.com, (734) 887-3903
Tiffany Aldrich, corporateteam@esperion.com, (616) 443-8438
Source: Esperion Therapeutics
